Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

First trial of a vaccine against Alzheimer’s launches

Researchers in the US hope that the vaccine can stimulate the brain’s immune system to clear the amyloid plaques seen in Alzheimer’s

- PMLiVE

PMEA 2021: A Celebration of Excellence in Patient Engagement

After hosting a virtual ceremony in 2020, this year’s awards returned to the Royal Lancaster London hotel

From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape

Joshua Yang, Co-founder & CEO of Glyphic Biotechnologies and Co-founder of NephroSant, dives into next-generation protein sequencing for biomedical research and clinical medicine, his journey from academia to entrepreneurship, and...

Impetus Digital

Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021

Toronto, ON, November 25, 2021– After a lengthy submission and voting process and amongst fierce competition, Impetus Digital has been selected as a winner of Canada’s Most Admired Corporate Cultures...

Impetus Digital

- PMLiVE

Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting

The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia

regeneron headquarters

Regeneron signs $900m cancer and infectious disease deal with Nykode

The deal with Norwegian clinical-stage vaccine specialist Nykode (previously Vaccibody) includes an upfront payment of $30m and an equity investment of $20m plus additional payments

Webcast: Securing a future for telehealth with immersive market research insights

Research Partnership investigate the current landscape, the challenges to adoption and the future for telehealth.

Inizio

- PMLiVE

Gilead’s Trodelvy approved for triple-negative breast cancer in Europe

European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy

- PMLiVE

AstraZeneca officially opens new R&D facility in UK

The high-tech £1bn research and development DISC facility in Cambridge, UK will see 2,000+ scientists housed in a building designed to the highest environmental standards

- PMLiVE

bluebird bio’s beti-cel accepted for priority review by FDA

The tough journey to approval for beta-thalassemia gene therapy (beti-cel) in the US may be coming to an end, with approval possible by 2022

- PMLiVE

US FDA expands COVID-19 booster jabs to all adults

All Americans 18 and over are now eligible to receive a booster shot of either the Pfizer/BioNTech or Moderna COVID-19 vaccines

- PMLiVE

Connecting capabilities in healthcare communications

The account management / medical writing paradigm was the cornerstone of medical communications for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's...

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links